hrp0084wg6.3 | Turner Syndrome | ESPE2015

Impact of Age at Start and GH Dose for Height Gain and Age at Adult Height in TS Girls

Kristrom Berit

Background: Early TS diagnosis permits early GH start and estradiol (E2) supplementation, approaching adult height (AH) at normal age and within normal range. However, higher age at diagnosis is still a challenge according to age for puberty induction and AH.Objective and hypotheses: The objective from our long term trials is knowledge enough for personalized treatment in order to obtain a psychological acceptable age at onset of puberty and still an att...

hrp0094p1-167 | Growth B | ESPE2021

Sex differences in growth response to GH treatment: more prepubertal and less pubertal gain in girls diagnosed with IGHD, ISS, SGA. Analysis of data from GH-SAFETY-database, including all children treated with rhGH- 1986-2009 in Sweden, in National-GH-Registry and rhGH-clinical-trials.

Lundberg Elena , Kristrom Berit , Pivodic Aldina , Albertsson-Wikland Kerstin ,

Background: Due to fewer girls than boys being GH-treated, after 50yrs the knowledge about sex-differences in both GH-response and GH-responsiveness before and during puberty remains limited.Aim: To describe factors explaining growth response to GH-treatment, separately in girls and boys from GHstart to adult height (AH).Methods: Children diagnosed with IGHD/ISS/SGA from GH-SAFETY-...

hrp0089rfc15.6 | Growth and syndromes | ESPE2018

Latest Results from PATRO Children, a Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope® in Children Requiring Growth Hormone Treatment

Kanumakala Shankar , Pfaffle Roland , Hoybye Charlotte , Kristrom Berit , Battelino Tadej , Zabransky Markus , Zouater Hichem

Objectives: PATRO Children is a non-interventional, international, longitudinal study of the long-term safety of a recombinant human growth hormone (rhGH; Omnitrope®, Sandoz). In particular, the study will assess the diabetogenic potential of rhGH and the risk of malignancies. The long-term efficacy is a secondary objective of the study.Methods: The study population includes infants, children and adolescents receiving Omnitrope®...

hrp0086p1-p630 | Growth P1 | ESPE2016

GH-Pattern with High Trophs are Often Found after Daily sc rhGH-Injection in Children

Lundberg Elena , Andersson Bjorn , Kristrom Berit , Rosberg Sten , Albertsson-Wikland Kerstin

Background: Endogenous GH pattern is characterized by high peaks (growth signal) and low trophs (metabolic signal). Exogenous GH is given by subcutaneous injection (scGH-injection) daily at bedtime.Objective and hypotheses: To study the factors influencing intra-/interindividual variation of pharmacokinetics and pattern of scGH-injection in GH treated children.Method: One hundred and twenty eight subjects followed yearly ≤ 8 ...

hrp0082p1-d2-150 | Growth (1) | ESPE2014

Cognitive Processing Speed as a Function of GH Treatment in Short Stature Children: a Multiple Regression Analysis

Chaplin John Eric , Kristrom Berit , Jonsson Bjorn , Tuvemo Torsten , Albertsson-Wikland Kerstin

Background: Cognitive function has been shown to improve following GH treatment in adults. In children born small for gestational age (SGA) IQ scores were found to improve following 24 months of GH treatment.Objective and hypotheses: The aim was to observe cognitive function in pre-pubertal, short children with isolated GH deficiency (IGHD) or idiopathic short stature (ISS) during the first 24 months of GH treatment. Cognitive testing was carried out usi...

hrp0084p1-137 | Turner & Puberty | ESPE2015

Normalization of Puberty and Adult Height in Girls with Turner Syndrome, Randomised Trials vs Age and Dose at GH-Start

Kristrom Berit , Ankarberg-Lindgren Carina , Barrenas Marie-Louise , Nilsson Karlolof , Albertsson-Wikland Kerstin

Background: Early TS diagnosis permits early GH start and estradiol (E2) supplementation approaching adult height (AH) at normal age and within a normal range. However, higher age at diagnosis is still a challenge.Objective and hypotheses: The hypothesis from our long-term trials will result in knowledge for personalized treatment in order to obtain a psychological acceptable age at onset of puberty and still an attained AH within normal range...

hrp0084p2-413 | GH & IGF | ESPE2015

Results up to January 2015 from PATRO Children, a Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope® in Children Requiring GH Treatment

Pfaffle Roland , Kanumakala Shankar , Hoybye Charlotte , Kristrom Berit , Schuck Ellen , Zabransky Markus , Battelino Tadej , Colle Michel

Background: PATRO Children is an international, open, longitudinal, non-interventional study designed to evaluate the long-term safety and efficacy of Omnitrope®, a biosimilar recombinant human GH (rhGH).Objective and hypotheses: Long-term safety of Omnitrope® is the primary objective of PATRO Children (particularly the diabetogenic potential of GH in short children born small for gestational age, the risk of malignancies,...

hrp0089p1-p239 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P1 | ESPE2018

Sustainability of Estradiol Drug Concentrations in Cut Matrix Patches; A Study of Different Brands with Potential Use for Pubertal Induction

Ankarberg-Lindgren Carina , Gawlik Aneta , Kristrom Berit , Mazzanti Laura , Sas Theo CJ

Background: The estimated estradiol (E2) dose required for pubertal induction in hypogonadal girls is about 1/10 of the adult dose. Previous studies have shown that it is possible to provide an individualized and physiological dose for pubertal induction by cutting the patch into smaller pieces. However, the manufacturers do not guarantee stability or utility of cut E2 patches, primarily designed for postmenopausal women, and have no interest in that eval...

hrp0086p1-p631 | Growth P1 | ESPE2016

Are the GH Treatment Doses in Use within Secretion Rates of Healthy Children?

Lundberg Elena , Andersson Bjorn , Kristrom Berit , Rosberg Sten , Albertsson-Wikland Kerstin

Background: GH-secretion rates for children ranges in pre/early puberty 0.1–11 U/24 h and during mid-puberty 4–40 U/24 h. This can be used to optimize the rhGH treatment doses in children.Objective and hypotheses: To calculated the bioavailable rhGH in relation to injected dose and compare this to GH-secretory rate in healthy children; and to investigate factors influencing bioavailability.Method: One hundred and twenty e...

hrp0082p2-d3-442 | Growth Hormone (2) | ESPE2014

Two-Year Results from Patro Children, a Multi-Centre, Non-Interventional Study of the Long-Term Efficacy and Safety of Omnitrope® in Children Requiring GH Treatment

Pfaffle Roland , Kanumakala Shankar , Hoybye Charlotte , Kristrom Berit , Schuck Ellen , Zabransky Markus , Battelino Tadej , Colle Michel

Background: PATRO children is an international, open, longitudinal, noninterventional study of the long-term safety and efficacy of Omnitrope®, a biosimilar recombinant human GH (rhGH).Objective and hypotheses: The primary objective is to assess the long-term safety of Omnitrope®, particularly the diabetogenic potential of GH in short children born small for gestational age, the risk of malignancies, and potential risks of...